These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 9663810)

  • 21. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits.
    Weinstock M; Gorodetsky E; Wang RH; Gross A; Weinreb O; Youdim MB
    Neuropharmacology; 2002 Nov; 43(6):999-1005. PubMed ID: 12423669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
    Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
    J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.
    Blob LF; Sharoky M; Campbell BJ; Kemper EM; Gilmor MG; VanDenberg CM; Azzaro AJ
    CNS Spectr; 2007 Jan; 12(1):25-34. PubMed ID: 17192761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans.
    Scheinin M; Koulu M; Vakkuri O; Vuorinen J; Zimmer RH
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):73-82. PubMed ID: 2300680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypotensive action and weak potentiation of tyramine effect by moclobemide in rats.
    Da Prada M; Burkard WP
    Acta Psychiatr Scand Suppl; 1990; 360():106-7. PubMed ID: 2248060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine.
    Korn A; Da Prada M; Raffesberg W; Gasic S; Eichler HG
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):17-23. PubMed ID: 2450251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.
    Schulz R; Antonin KH; Hoffmann E; Jedrychowski M; Nilsson E; Schick C; Bieck PR
    Clin Pharmacol Ther; 1989 Nov; 46(5):528-36. PubMed ID: 2510962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of chronic administration of ciclazindol and desipramine on pupillary responses to tyramine, methoxamine and pilocarpine in healthy volunteers.
    Kerr FA; Szabadi E
    Br J Clin Pharmacol; 1985 May; 19(5):639-47. PubMed ID: 4005103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of adverse interactions between concomitantly administered selegiline and citalopram.
    Laine K; Anttila M; Heinonen E; Helminen A; Huupponen R; Mäki-Ikola O; Reinikainen K; Scheinin M
    Clin Neuropharmacol; 1997 Oct; 20(5):419-33. PubMed ID: 9331518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects.
    Dingemanse J; Berlin I; Payan C; Thiede HM; Puech AJ
    Psychopharmacology (Berl); 1992; 106 Suppl():S68-70. PubMed ID: 1546145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemistry and pharmacology of moclobemide, a prototype RIMA.
    Haefely W; Burkard WP; Cesura AM; Kettler R; Lorez HP; Martin JR; Richards JG; Scherschlicht R; Da Prada M
    Psychopharmacology (Berl); 1992; 106 Suppl():S6-14. PubMed ID: 1546143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine.
    Gieschke R; Schmid-Burgk W; Amrein R
    J Neural Transm Suppl; 1988; 26():97-104. PubMed ID: 3283292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-clinical pharmacology of moclobemide. A review of published studies.
    Burkard WP; Da Prada M; Keller HH; Kettler R; Haefely W
    Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The current status of monoamine oxidase and its inhibitors.
    Jarrott B; Vajda FJ
    Med J Aust; 1987 Jun; 146(12):634-8. PubMed ID: 3114597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
    Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
    J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of platelet monoamine oxidase type B by selegiline.
    Heinonen EH; Anttila MI; Nyman LM; Pyykkö KA; Vuorinen JA; Lammintausta RA
    J Clin Pharmacol; 1997 Jul; 37(7):597-601. PubMed ID: 9243352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of moclobemide and tricyclic antidepressants with the tyramine pressor effect in rats.
    Burkard W; d'Agostini F; Kettler R; Da Prada M
    Psychopharmacology (Berl); 1992; 106 Suppl():S35-6. PubMed ID: 1546137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dynamic light-evoked pupillometry for the differentiation of psychotropic substances].
    Grünberger J; Linzmayer L; Cepko H; Saletu B
    Arzneimittelforschung; 1987 Mar; 37(3):357-60. PubMed ID: 3593452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
    Bieck PR; Antonin KH
    J Neural Transm Suppl; 1989; 28():21-31. PubMed ID: 2794993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide.
    Dingemanse J; Hussain Y; Korn A
    Int J Clin Pharmacol Ther; 1996 Apr; 34(4):172-7. PubMed ID: 8861736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.